higher dollar is good to CRXL

[Entendance]

CRXL: add under $24
More Potential Drug Industry Mergers
http://seekingalpha.com/article/125157- ... ry-mergers

[Entendance]

Crucell Announces Release 2008 Annual Report and Form 20-F

Leiden, The Netherlands (April 24, 2009) - Dutch biopharmaceutical company Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) today announced the release of its 2008 Annual Report and Form 20-F.

The full report is available at:
http://www.crucell.com/page/downloads/8 ... _Final.pdf
http://www.crucell.com/

[Entendance]

CRXL our long-term winner
http://www.cnbc.com/id/15840232?play=1& ... &par=yahoo

http://finviz.com/quote.ashx?t=crxl

[Entendance]

Swine Flu Stock #3: Crucell
Crucell (CRXL) is the 21st-century vaccine technology company, and its business model is to be the "Intel Inside" for many vaccine makers. Crucell owns a traditional vaccine business and is also developing new vaccines for many infectious diseases.

Its technology platform -- cell-line manufacturing -- is much more efficient than traditional egg-based vaccine production, and the company has partnered with many of the major players in the vaccine business.
http://www.optionszone.com/trading-idea ... part2.html

[defio70]

Aeras and Crucell Announce Start of TB Infant Study in South Africa

Leiden, The Netherlands / Rockville, MD, USA - April 28, 2009 - Dutch biopharmaceutical company Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) and the Aeras Global TB Vaccine Foundation today announced the start of a Phase I clinical trial in infants of the jointly developed tuberculosis (TB) vaccine candidate, AERAS-402/Crucell Ad35. This is the first clinical trial designed to test this vaccine candidate in infants.
http://www.crucell.com/

Crucell statement on Swine Flu
Tuesday, 28 April 200
As an influenza vaccine manufacturer Crucell is aware of the current situation in Mexico and other affected countries. Crucell is in active dialogue with the relevant governmental authorities and non governmental organizations (NGOs), while suitable actions to the situation are being decided. As an active member of the International Vaccine Supply Task Force and the International Federation of Pharmaceutical Manufacturers and Associations, Crucell will work with other industry members, health authorities and NGOs to respond as rapidly as possible and in accordance with key recommendations made by the World Health Organization (WHO). In response to a request from the Pan American Health Organization, Crucell is looking to mobilize remaining (limited) stocks of its 2008/2009 seasonal vaccine Inflexal® V for supply to Mexico. Although at this stage it is not clear if existing seasonal flu vaccines induce protective immunity to the currently circulating H1N1 swine flu virus strain. The situation appears to be evolving rapidly, therefore Crucell's response will be tailored to support the public health needs, once more information becomes available, and as directed by organizations such as the WHO.

Crucell has an active influenza R&D program to improve the prevention and treatment of seasonal and pandemic influenza:

Crucell is testing new adjuvants and new routes of administration in humans for virosome-based pandemic influenza vaccines in the EU (Panfluvac program).
Sanofi Pasteur is using Crucell's PER.C6® technology to produce the next generation influenza vaccines.
Crucell has discovered human monoclonal antibodies broadly protecting against H1 strains to which family the current swine flu virus belongs. The most potent and broadly reactive of these antibodies is currently being prepared for clinical testing.

[sowhat]

Crucell to Release First Quarter 2009 Results on Wednesday, May 6, 2009
Leiden, The Netherlands (April 29, 2009) - Dutch biopharmaceutical company Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) today announced that it will release its financial results for the first quarter 2009 on Wednesday, May 6, 2009 at 07:45 Central European Time (CET).

[Entendance]

Crucell Remains Takeover Target, expecially now.
We hope to see CRXL over $40 before summer. Not far from valuations we heard when Wyeth thought about potential combination of the two companies.

[defio70]

CDC: Swine flu now confirmed in ten states


http://www.marketwatch.com/news/story/C ... 895D413%7D

[Entendance]

<...Most drug companies still produce flu vaccines using a decades-old process. They inject a version of the virus into the embryos of millions of chicken eggs. The eggs are incubated for several months, and then the whites are extracted and blended into vaccine.
Newer technology allows for the faster creation of flu vaccines using cell cultures. But there are few such facilities. Novartis has one in Germany and is building another in North Carolina.>
http://online.wsj.com/article/SB1241050 ... outset-box
CRUCELL STRATEGIC PARTNERS
http://www.crucell.com/Partners_-_Strategic_Partners

[Entendance]

<...Novartis (NVS 37.88 ↑0.00%), Baxter, and Crucell (CRXL 20.764 ↑0.00%) are each developing vaccine-production methods to replace our antiquated system (which uses chicken eggs). From start to finish, each of the new approaches can generate an original vaccine within 12 to 16 weeks.
Novartis already has the genetic code of the current swine flu virus. Now, it’s waiting for an actual sample of the virus to arrive in its labs. Baxter expects a sample, as well, in the next few days.
Of these three players, my favorite is Crucell. As a pioneer of cell-based technology, this Dutch-based biotech company has successfully used its platform to develop new vaccines, drugs, and research products with dozens of partners.
So, ignore the hype from names like Novavax and BioCryst. These stocks will end up right where they started (if not lower) after the media drops swine flu for the next big story.
If you want to profit when this round of fear translates into stepped up vaccine sales next winter and more government stockpiles, stick with the four names above>
http://jutiagroup.com/2009/05/01/dont-g ... lu-trades/